[go: up one dir, main page]

Shiue et al., 2001 - Google Patents

A simplified one-pot synthesis of 9-[(3-[18F] fluoro-1-hydroxy-2-propoxy) methyl] guanine ([18F] FHPG) and 9-(4-[18F] fluoro-3-hydroxymethylbutyl) guanine ([18F] …

Shiue et al., 2001

Document ID
11815726017828911392
Author
Shiue G
Shiue C
Lee R
MacDonald D
Hustinx R
Eck S
Alavi A
Publication year
Publication venue
Nuclear medicine and biology

External Links

Snippet

9-[(3-[18F] Fluoro-1-hydroxy-2-propoxy) methyl] guanine ([18F] FHPG, 2) has been synthesized by nucleophilic substitution of N2-(p-anisyldiphenylmethyl)-9-{[1-(p- anisyldiphenylmethoxy)-3-toluenesulfonyloxy-2-propoxy] methyl} guanine (1) with …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0476—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from monodendate ligands, e.g. sestamibi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules

Similar Documents

Publication Publication Date Title
Alauddin et al. Evaluation of 9-[(3-18F-fluoro-1-hydroxy-2-propoxy) methyl] guanine ([18F]-FHPG) in vitro and in vivo as a probe for PET imaging of gene incorporation and expression in tumors
Shiue et al. A simplified one-pot synthesis of 9-[(3-[18F] fluoro-1-hydroxy-2-propoxy) methyl] guanine ([18F] FHPG) and 9-(4-[18F] fluoro-3-hydroxymethylbutyl) guanine ([18F] FHBG) for gene therapy
Luker et al. Beyond the genome: molecular imaging in vivo with PET and SPECT
Rousseau et al. Effects of adding an albumin binder chain on [177Lu] Lu-DOTATATE
US20130343990A1 (en) Radiolabelled octreotate analogues as pet tracers
Alauddin et al. In vivo evaluation of 2′-deoxy-2′-[18F] fluoro-5-iodo-1-β-D-arabinofuranosyluracil ([18F] FIAU) and 2′-deoxy-2′-[18F] fluoro-5-ethyl-1-β-D-arabinofuranosyluracil ([18F] FEAU) as markers for suicide gene expression
US5703056A (en) Non-invasive imaging of gene transfer
Miao et al. Reducing renal uptake of 90Y-and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues
Müller et al. Single photon emission computed tomography tracer
Potemkin et al. Development of 18F-fluoroglycosylated PSMA-ligands with improved renal clearance behavior
Ibrahim et al. Radioiodinated doxorubicin as a new tumor imaging model: preparation, biological evaluation, docking and molecular dynamics
Läppchen et al. In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector
EP2776382B1 (en) 18f-saccharide-folates
Chakraborty et al. Tracer level radiochemistry to clinical dose preparation of 177Lu-labeled cyclic RGD peptide dimer
Li et al. FAP-targeted delivery of radioiodinated probes: A progressive albumin-driven strategy for tumor theranostics
Alauddin et al. Evaluation of 2′-Deoxy-2′-Flouro-5-Methyl-1-β-d-Arabinofuranosyluracil as a potential gene imaging agent for HSV-tk expression in vivo
Oum et al. A benzenesulfonamide derivative as a novel PET radioligand for CXCR4
Jin et al. PSMA and SSTR2 Dual-Targeting Theranostic Agents for Neuroendocrine-Differentiated Prostate Cancer (NEPC)
Zhang et al. Synthesis, radiolabeling, and evaluation of a (4-quinolinoyl) glycyl-2-cyanopyrrolidine analogue for fibroblast activation protein (FAP) PET imaging
Li et al. Development of a Radiotracer for PET Imaging of the SNAP Tag
US20110236312A1 (en) Nucleoside analogues useful as positron emission tomography (pet) imaging agents
Abouzayed et al. 177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry
M. Alauddin et al. Radiolabeled nucleoside analogues for PET imaging of HSV1-tk gene expression
Yang et al. 99mTc-EC-guanine: synthesis, biodistribution, and tumor imaging in animals
Nanda et al. Imaging expression of adenoviral HSV1-tk suicide gene transfer using the nucleoside analogue FIRU